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Background: VopS is a bacterial effector that 
AMPylates Rho GTPases  
Results: AMPylation of Rho GTPases inhibits 
their interaction with multiple downstream 
effectors  
Conclusion: VopS conducts a multifaceted host 
signaling inhibition program by targeting the 
critical Rho GTPases 
Significance: Broadens understanding of how 
switch-1 modification of Rho GTPases affects 
host responses  
 
Abstract 
Rho GTPases are frequent targets of 
virulence factors as they are keystone 
signaling molecules. Herein, we demonstrate 
that AMPylation of Rho GTPases by VopS is 
a multifaceted virulence mechanism that 
counters several host immunity strategies. 
Activation of NFκB and JNK kinase signaling 
pathways were inhibited in a VopS dependent 
manner during infection with Vibrio 
parahaemolyticus. Phosphorylation and 
degradation of IKBα were inhibited in the 
presence of VopS, as was nuclear 
translocation of the NFκB subunit p65. 
AMPylation also prevented the generation of 
superoxide by the phagocytic NADPH 
oxidase complex. Furthermore, the 
interaction of GTPases with the E3 ubiquitin 
ligases cIAP1 and XIAP was hindered, 
leading to decreased degradation of Rac and 
RhoA during infection. Finally, we screened 
for novel Rac1 interactions using a nucleic 
acid programmable protein array and 
discovered that Rac1 binds to the protein 
C1QA, a protein known to promote immune 
signaling in the cytosol. Interestingly, this 
interaction was disrupted by AMPylation. We 
conclude that AMPylation of Rho Family 
GTPases by VopS results in diverse 
inhibitory consequences during infection 
beyond the most obvious phenotype, the 
collapse of the actin cytoskeleton.  
Rho GTPases are proteins that are integral in 
diverse signaling pathways, including the 
maintenance of cell structure, coordination of 
cell motility, response to extracellular stimuli 
and activation of host defenses to pathogens. 
Accordingly, they represent a ripe target for 
virulence mechanisms of pathogenic bacteria 
and are frequently modified with post-
translational modifications, such as 
glucosylation, deamidation and AMPylation (1-
3) . The switch-1 loop of GTPases is a frequent 
target of such modifications because this region 
 JBC
 
C
 o
 n
 f 
i d
 e 
n 
t i
 a
 l
Rho GTPase AMPylation inhibits signaling pathways 
 
 
2 
 
 
of the protein mediates interactions with 
downstream signaling partners, such as p21-
activated kinase (PAK) (4). The attractiveness of 
this family of proteins as targets for pathogens is 
highlighted by recent discoveries of host pattern 
recognition receptors (PRRs) that monitor the 
activation status of Rho GTPases. NOD family 
proteins were shown to be PRRs that sense 
activated Rac1 and stimulate NFκB signaling 
(5). Inversely, Rho proteins that have been 
inactivated through modification of the switch-1 
loop can trigger the inflammasome through the 
novel PRR protein Pyrin via an unknown 
mechanism (6). The sensitivity of the host 
immune system to modulation of Rho GTPases 
may merely be a convenient way to sense 
infection, or it may instead suggest that these 
modifications are exceptionally deleterious to 
the host. The majority of investigations about 
the effect of Rho GTPase posttranslational 
modifications, including AMPylation, have 
focused on the collapse of the actin 
cytoskeleton, but other signaling pathways in 
which these GTPases are involved may also be 
affected (7,8).  
One example of Rho GTPase targeting 
by virulence factors is the targeting of Rho, Rac 
and CDC42 by the type three secreted effector 
VopS from Vibrio parahaemolyticus, a pathogen 
that causes gastroenteritis as a result of the 
consumption of contaminated undercooked 
seafood and septicemia in cases of wound 
infection or immune compromised patients (1). 
This protein is delivered into host cells via the 
first of two type three secretion systems (T3SS1) 
encoded in the pathogen’s genome. The T3SS1 
causes an orchestrated death of the host cell in 
less than three hours that involves effector-
induced apparent autophagy by VopQ, plasma 
membrane blebbing by VPA0450, cell rounding 
by VopS and, finally, host cell lysis caused by 
all secreted effectors working together in concert 
(9-11). The second type three secretion system 
of V. parahaemolyticus (T3SS2) is responsible 
for gastroenteritis in infected individuals and has 
been implicated in invasion of infected host cells 
(12). Upon delivery into the host cell, VopS 
localizes to the plasma membrane via its 
bacterial phosphoinositide-binding domain, 
where it modifies Rho GTPase proteins by 
adding an adenosine monophosphate (AMP) to a 
threonine located in the switch-1 loop of the 
GTPase (13,14). This modification has been 
demonstrated to cause actin cytoskeletal collapse 
by blocking interaction of Rac1 with p21-
Activated Kinase (PAK) (1). This phenotype has 
obvious implications for an infected host, but its 
drastic nature likely masked other important 
cellular consequences. In support of this, VopS 
has previously been shown to reduce cytokine 
production during infection through an unknown 
mechanism (15).  
Rho family GTPases are known to have 
many functions in the cell beyond control of the 
actin cytoskeleton. For example, Rac has been 
shown to perform several functions in innate 
immunity, such as activation of the phagocytic 
NADPH oxidase complex, which is important 
for microbial killing by lymphocytes. 
Association of activated Rac is essential for the 
recruitment of the p67phox subunit to the 
membrane, allowing generation of the killing 
superoxides at the phagocytic cup (16). Rac is 
also a known ubiquitination substrate for the 
Inhibitors of Apoptosis proteins (IAPs), though 
the full implications of this modification are 
unclear (17). IAP’s are known to ubiquitinate 
TRAF6 and several other proteins as a result of 
microbial and other stimuli to initiate 
downstream signaling of NFκB and MAPK 
pathways, leading one to speculate that Rho 
GTPase ubiquitination might play a role in these 
pathways (18). The NFκB and MAPK signaling 
cascades are critical systems that mediate cell 
survival outcomes for a variety of cell responses 
to outside stimuli, and their importance during 
bacterial infection is well established (19). 
Manipulating these pathways are a common goal 
of many pathogenic bacteria, and several other 
diverse strategies have been elucidated, 
including, but not limited to, Ser/Thr acetylation, 
ubiquitination, phosphothreoninelyation, 
deamidation and ADP-ribosylation (20).  
We sought to determine whether 
AMPylation of the Rho GTPase switch-1 region 
by VopS had effects beyond the collapse of the 
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actin skeleton. To this end, we monitored the 
effects of VopS during infection on NFκB and 
MAPK signaling pathways, binding of IAP 
proteins to Rac1, and the ability of Rac1 to 
activate the phagocytic oxidase complex. Each 
of these signaling processes plays important 
roles in the ability of a host to clear infection, 
and we found that VopS had striking inhibitory 
effects on all of them. We also utilized a broad 
proteomic screen to identify a novel Rac1 
binding protein C1qA. This interaction is 
hampered by VopS-mediated AMPylation, and 
thus may have implications in immunity that are 
yet to be explored.  
 
Experimental Procedures 
Antibodies-Rac, RhoA, phospho-IκBα,  and 
phospho-p38 antibodies were purchased from 
Cell Signaling Technologies (Danvers, MA). 
The anti-threonine AMPylation antibody has 
been previously described (21). p65/RelA, 
cIAP1, tubulin, IκBα, JNK, and phospho-JNK 
antibodies were purchased from Santa Cruz 
Biotechnology. Antibodies were used in 
manufacturer’s recommended antibody solutions 
and concentrations where applicable.  
Plasmid constructs-C-terminal GST fusions of 
cIAP1, XIAP, C1qA, RhoB and all printed 
NAPPA cDNAs used for cell free expression 
assays were encoded in the pANT7-cGST vector 
from the Arizona State University DNASU 
program: dnasu.org/DNASU. Rac1 V12 was 
cloned into pET-28a. VopS Nd30 was cloned 
into pGEX-TEV for protein purification, and full 
length VopS was cloned into pLAFR and 
pBAD33 along with its 1kb upstream genomic 
sequence for V. parahaemolyticus reconstitution 
as detailed in Bacterial Strains and Table 1. 
Tissue culture conditions-HEK293T cells were 
maintained in DMEM (Gibco) containing 10% 
fetal bovine serum (FBS) and 
penicillin/streptomycin/glutamine at 37°C with 
5% CO2. COSphox cells were maintained in low 
glucose DMEM (Hyclone) with 10% FBS, 
penicillin/streptomycin, 0.8 mg/ml G418, 200 
µg/ml hygromycin and 1 µg/ml puromycin at 
37°C with 5% CO2.  
Bacterial strains- Escherichia coli strain Rosetta 
(DE3) used for protein purification was cultured 
with chloramphenicol in addition to antibiotics 
for plasmid selection. Vibrio parahaemolyticus 
strains are listed in Table 1 and were derived 
from POR1 (RIMD2210633 ∆tdhAS), which 
was generously provided by Drs. Tetsuya Iida 
and Takeshi Honda. Strain genotypes and 
characteristics are detailed in Table E1. POR3 
contains a deletion of VcrD2 that renders the 
second T3SS inactive. The CAB5 strain contains 
a deletion for the transcriptional regulator VtrA 
to prevent expression of the second T3SS, as 
well as deletions of the effectors VopQ, VopR, 
and VPA0450 to leave VopS as the only known 
T3SS effector expressed and secreted. VopS was 
further deleted in the CAB5∆vopS strain, and 
complemented with a pBAD-VopS expression 
plasmid containing VopS wild type or VopS-
H348A preceded by 1kb of its upstream 
sequence, which typically allows expression and 
secretion levels similar to genes encoded in the 
genome. POR3∆vopS was complemented in the 
same manner, but using the pLAFR cosmid. 
Routine culture, deletions and reconstitution via 
plasmid mating were performed as previously 
described (22). 
Bacterial infection experiments-For immunoblot 
experiments, cells were seeded onto 6-well 
plates at a density of 4x105 cells per well the day 
prior to infection. For immunofluorescence 
experiments, cells were seeded on 6-well plates 
containing sterile cover slips at a density of 
1x105 cells per well. Bacteria were induced prior 
to infection by diluting overnight culture 1:10 
into plain DMEM, followed by incubation at 
37°C with shaking for 30 minutes. Bacteria were 
then diluted to MOI 10 relative to host cells in 
fresh pre-warmed DMEM. Culture media on 
cells was then replaced with this infection 
media, and were spun at 1000 rpm for 5 minutes 
prior to return to the incubator for indicated 
infection times. All infection experiments were 
performed three or more times with consistent 
results. 
Immunoblot and immunofluorescence-For 
immunoblotting, cells were lysed in buffer 
containing 50 mM Tris pH 8.0, 150 mM NaCl, 1 
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mM EDTA, 5% glycerol, and 1% NP-40 with 
protease and phosphatase inhibitors (Roche) on 
ice prior to electrophoresis and immunoblotting. 
PVDF membranes were blocked with 5% milk 
for 30 minutes and incubated with primary 
antibodies at 4°C overnight with agitation. 
Secondary HRP linked antibodies (donkey anti-
rabbit, GE; goat anti-mouse, Sigma; donkey 
anti-goat, Santa Cruz) were incubated at room 
temperature for 30 minutes at 1:10,000 dilutions 
in 5% milk followed by thorough washing in 
TBST. Chemiluminescence was generated using 
the Pierce ECL2 HRP substrate. For 
immunofluorescence experiments, cells were 
washed once with PBS, followed by fixing in 
3.2% PFA. Fixed cells were permeabilized with 
0.5% Triton-X-100 in PBS prior to 
immunostaining with anti-p65 (Santa Cruz) at a 
1:200 dilution for 1 hour. Staining was detected 
with anti-rabbit Alexa Fluor 568 secondary 
antibody (Life Technologies) incubation at 
1:500 dilution for 1 hour. DNA was visualized 
by staining with Hoescht at 1 µg/ml for 10 
minutes. Confocal images were taken using a 
Zeiss LSM 710 microscope and converted using 
ImageJ.  
Recombinant protein purification-Tag free VopS 
protein was purified as previously described 
(14). AMPylated and unAMPylated His-Rac1 
V12 were purified by coexpression in Rosetta 
(DE3) E. coli with a GST-VopS fusion or empty 
vector. Cultures were grown to approximately an 
OD600 of 0.6 at 37°C and protein expression was 
induced by the addition of 0.4 mM isopropyl β-
D-thiogalactopyranoside for 4 hours at room 
temperature. His-Rac1 proteins were isolated on 
Ni2+ agarose (Pierce), followed by gel filtration 
chromatography on Superdex 75 PG with an 
AKTA FPLC system. Fractions containing pure 
Rac1 were pooled, concentrated and frozen in 
10% glycerol at -80°C. The secondary 
AMPylation assay was performed by incubating 
Rac proteins with VopS and 0.5 uCi 32P-α-ATP 
for 30 minutes at 30°C prior to electrophoresis, 
transfer and phosphoimaging. GST-PAK3 PBD 
and and GST-p67 were expressed as above and 
purified with glutathione agarose (Pierce). GST-
cIAP1, XIAP, C1qA and RhoB fusions were 
expressed in the human cell-free system 
(ThermoFisher Scientific) prior to 
immunoprecipitations. 
Pull-downs and immunoprecipitations-GST 
pull-downs were performed by incubating 
purified GST-proteins with His-Rac1 V12 at 
4°C with agitation for 2 hours, followed by 
incubation with washed glutathione agarose for 
1 hour. Beads were washed 4 times in TBST 
prior to elution in Laemmli buffer. 
Immunoprecipitations were performed by 
loading anti-GST-bound magnetic protein A/G 
beads with GST-fusions expressed in cell-free 
lysates. GST beads were then incubated with 
purified His-Rac1 V12 and washed as above.  
Superoxide generation assay-COSphox cells 
were seeded at a density of 2x105 cells per well 
in a 6-well plate, followed by infection as 
described above. Cells were then collected and 
superoxide generation upon stimulation with 
Phorbol 12-myristate 13-acetate (PMA, Sigma) 
was measured using the Diogenes kit (National 
Diagnostics) according to manufacturer’s 
protocol. Luminescence was monitored using a 
FLUOstar OPTIMA (BMG LabTech) plate 
reader over 30 minutes. Superoxide assays were 
performed three times in triplicate and a 
representative experiment is shown. 
NAPPA interaction screen-The fabrication of 
NAPPA arrays comprising of 10,000 highly 
purified DNA plasmids with full-length human 
ORF sequences and the procedure of protein-
protein interaction screens were reported as 
previously described (23,24). Briefly, to 
accomplish the expression & display of proteins 
on NAPPA, the array was blocked with the 
Superblock solution (Pierce, Rockford, IL) for 
1h at 23oC, and then incubated with the HeLa 
lysates based cell-free expression system 
(Thermo scientific, Rockford, IL) for 1.5hrs at 
30oC and 0.5hrs at 15oC. After brief washing 
with PBST (PBS, 0.2%Tween), the resulting 
protein array was blocked with PPI COLD 
blocking buffer (1×PBS, 1%Tween 20 and 1% 
BSA, pH7.4) for 1 hr at 4oC. In parallel, 100 
ng/µL DNA of Rac1-Halo proteins was added in 
170 µL human HeLa lysates based cell-free 
expression system, and the expression was 
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performed at 30oC for 2hrs. To execute protein-
protein interaction screening, the expressed 
Rac1-Halo proteins was incubated with NAPPA 
protein array for 16hrs at 4oC. After reaction, the 
array was washed three times with PPI washing 
buffer (PBS, 5 mM MgCl2, 0.5% Tween20, 1% 
BSA and 0.5% DTT, pH7.4). The binding of 
Rac1-Halo to its interactors on NAPPA was 
detected using 12.5 µM Alexa 660 conjugated 
Halo-ligand (Promega, Madison, WI). Finally, 
the microarray fluorescent images were scanned 
using Tecan’s PowerScanner (Männedorf, 
Switzerland) and the signal intensity was 
quantitated using Array-Pro Analyzer (Media 
Cybernetics, Bethesda, MD). 
Selection of Rac1 interactors from NAPPA 
screening-The selection of interaction targets 
was executed as previously described (24). 
Briefly, all NAPPA images were visually 
examined to eliminate the false positive signals 
caused by the spot shape, dust and non-specific 
bindings. Signal normalization was performed 
using the raw signal intensity of each spot 
divided by the median background-adjusted 
value of all features on the array. Finally, the Z-
score was calculated for each protein and the 
selection of Rac1 interactor candidates using the 
following criteria (1) Z-score ≥ 2.5; (2) Z-score 
ratio of query protein to Halo negative control ≥ 
2; (3) the targets have to meet previous criteria 
in two independent experiments.   
wNAPPA assays-The detail of wNAPPA was 
executed as previously described with minor 
modifications (25). Briefly, the anti-GST 
antibody coated 96-well plate (GE Healthcare 
Life Sciences, PA) was blocked with 5% milk at 
4oC overnight.  In parallel, the RhoGTPase 
proteins containing a c-terminal Halo tag and 
their interaction proteins containing a c-terminal 
GST tag were expressed in 30 µL human HeLa 
lysates based cell-free expression system using 
40 ng/µL DNA, with or without 5 ug of purified 
VopS added to the lysate. After expression, they 
were diluted with 100µL PPI blocking buffer 
and added into the 96-well plate. The protein-
protein interaction reaction was then executed at 
15oC for 2hrs on the shaker (Eppendorf, 
Hamburg, Germany) with 1,000rpm. After 
washing three times with PBST, the detection 
was accomplished by incubation with 1:3000 
diluted anti-Halo tag antibody (Promega, 
Madison, WI), 1:000 diluted HRP labeled goat 
anti rabbit IgG antibody (Jackson 
ImmunoResearch, West Grove, PA) and TMB 
colorimetric HRP substrates (Thermo Scientific, 
Waltham, MA), respectively.  
 
Results 
VopS AMPylation inhibits NFκB and JNK 
signaling-The MAP kinase and NFκB signaling 
pathways are central in pathogen recognition 
and response by the immune system, and are 
known to be activated downstream of multiple 
receptors during bacterial infection (26). NFκB 
is an important modulator of cell survival during 
microbial infection. When activated, Rel 
proteins in this system propagate anti-apoptotic 
and pro-inflammatory signals by translocating to 
the nucleus and activating the transcription of 
relevant factors, such as immune regulating 
cytokines (26). Translocation of Rel proteins, 
such as p65, are inhibited when such stimulus is 
absent by the binding of the inhibitory protein 
IκBα, which sequesters them in the cytosol. 
When the NFκB pathway is stimulated, IκBα is 
phosphorylated by IKK, targeting it for 
ubiquitination and degradation. A common 
method of measuring NFκB activation under 
various stimuli is to monitor the phosphorylation 
and degradation of IκBα, which allows p65 and 
other Rel proteins to translocate to the nucleus.  
To assess the effect of VopS on host 
signaling, we infected cells with V. 
parahaemolyticus strains rather than transfecting 
cells with VopS. Transfection of cells with 
VopS causes cell rounding within 8 hours, 
precluding our ability to follow the kinetics of 
VopS-induced inhibition of a signaling pathway.  
For analysis of NFκB signaling we infected 
HEK293T cells with the V. parahaemolyticus 
strain POR3, which is an attenuated clinical 
isolate that is deleted for its TDH toxins and the 
second T3SS (T3SS2), thereby allowing T3SS1 
to be studied independent of the other known V. 
parahaemolyticus virulence factors. During 
infection with POR3 we found that IκBα 
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phosphorylation and degradation of IκBα was 
markedly reduced relative to a POR3 strain that 
is deleted for VopS (POR3∆vopS). Unlike 
POR3, infection with POR3∆vopS resulted in 
strong IκBα phosphorylation concomitant with 
decreased IκBα protein levels within 1 hour of 
infection (Fig. 1). IκBα phosphorylation and 
degradation during infection with POR3∆vopS 
complemented with wild type VopS 
(POR3∆vopS/pVopS) was similar to the parental 
POR3 strain, though total AMPylation of Rho 
GTPases was not as efficient.  
To corroborate this observation, we 
performed anti-p65/RelA immunofluorescence 
of HEK293T cells infected with the CAB5 
strain. This strain lacks the TDH toxins, the 
second T3SS and other known T3SS1 effectors, 
including VopQ, VopR and VPA0450, leaving 
VopS as the only remaining known T3SS1 
effector. Removal of these effectors reduces 
cytotoxicity against tissue culture cells that 
might mask relevant phenotypes. After 2 hours 
of infection with this strain, only 18% of cells 
showed strong p65 nuclear localization (Fig. 
2A). In contrast, greater than 95% of cells 
infected with CAB5∆vopS, which contains a 
further deletion for VopS, showed nuclear p65 
localization. Complementation of this phenotype 
was observed in cells infected with the 
CAB5∆vopS strain reconstituted for wild type 
VopS, CAB5∆vopS/pVopS, with approximately 
48% p65 translocation. Therefore, we observe 
p65 localization during infection in the absence 
of VopS and inhibition of this nuclear 
localization in the presence of VopS (Fig. 2B). 
The MAP kinases p38 and c-jun 
activated kinase (JNK) are commonly activated 
during infection, and along with NFκB share 
many upstream activators that can be activated 
by Rho GTPases (27). Activation of these 
proteins is characterized by phosphorylation of 
their activation loops on their signature –TXY- 
motifs. With profiles similar to IκBα activation, 
we found that during infection with V. 
parahaemolyticus POR3 and 
POR3∆vopS/pVopS, JNK activation was 
inhibited (Fig. 1). p38 activation did not appear 
to be affected by VopS, and the POR3∆vopS 
strain induced activation of both p38 and JNK. 
This observation indicates that NFκB, p38 and 
JNK are activated during V. parahaemolyticus 
infection and that VopS disrupts an upstream 
activator of shared by NFκB and JNK, but not 
p38.  
AMPylation of Rho GTPases blocks their 
interaction with Inhibitor of Apoptosis proteins-
IAP proteins are well studied factors in their 
inhibition of apoptosis and activation of NFκB, 
but the breadth of their involvement in these 
processes is not well understood. Their E3 ligase 
activity is important for this function, as 
ubiquitination of target substrate proteins is 
required to create necessary docking sites for 
interactions between proteins in the NFκB 
pathway, such as TRAF proteins (28). 
Interestingly, IAPs were recently found to also 
be E3 ligases for Rac1 (17). It is not known if 
the ubiquitination of Rac proteins by IAP’s 
might play a role in infection and NFκB 
activation, or if it merely targets them for 
proteosomal degradation. To test if AMPylation 
of Rac1 might disrupt this interaction, we 
generated AMPylated His-Rac1-V12, a 
dominant active mutant, by coexpression with 
VopS in E. coli. Rac-V12 previously 
coexpressed with VopS is insensitive to further 
AMPylation in a secondary AMPylation assay, 
indicating that nearly all of the protein is 
modified (Fig. 3A). AMPylated Rac1 also 
showed no interaction with PAK, as 
demonstrated previously (Fig. 3B, (1)). GST 
fused cIAP and XIAP were then incubated with 
recombinantly purified His-Rac1-V12. 
Unmodified Rac1 bound readily to both cIAP 
and XIAP, but AMPylated His-Rac1-V12 did 
not bind either protein (Fig. 4A), demonstrating 
that AMPylation may disrupt this direct 
interaction.  
 To determine if IAPs might bind other 
Rho GTPases, we prepared a NAPPA interaction 
assay in a 96 well microplate format (wNAPPA) 
(25,29). After incubation of the ELISA plate 
with the Halo-tagged Rac1, CDC42 or RhoA 
with or without the addition of recombinant 
VopS, we confirmed that IAP proteins were able 
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to bind unAMPylated but not AMPylated Rac1, 
CDC42 and RhoA (Fig. 4B). CDC42 and RhoA 
have not previously been shown to be binding 
partners of cIAP. 
Next, we analyzed whether disruption of 
the interaction between IAPs and GTPases 
might have functional consequences during an 
infection. We infected HEK293T cells with 
CAB5 and found that although the expression of 
cIAP1 was enhanced during infection, we 
observed only a small reduction in the levels of 
Rac1 and Rho. By contrast, the increase in cIAP 
was coincident with a marked decrease in total 
levels of Rac1 and RhoA protein when infected 
with CAB5∆vopS (Fig. 4C) and by 4 hours Rac 
and Rho were nearly undetectable. Infection 
with CAB5∆vopS/pVopS prevented this 
degradation. Based on our previous observations 
that the cIAPs can no longer interact with 
AMPylated Rac1 and Rho, we propose this 
modification is preventing targeted degradation 
of these RhoGTPases by cIAP1. 
The phagocytic NADPH oxidase complex is 
inhibited by AMPylation-Microbial killing by 
lymphocytes is largely a function of 
phagocytosis followed by generation of reactive 
oxygen species (ROS) to kill the engulfed 
microbes (30). The phagocytic NADPH oxidase 
(NOX2) complex, which is composed of at least 
5 proteins, generates these superoxides at the 
site of engulfment, which activates proteolytic 
enzymes that mediate killing and immune 
signaling (31). The complex is composed of 
gp91, p22, p47, p67 and Rac1 or Rac2. Rac1/2 is 
essential for the function of the complex, as its 
activation, localization to the membrane and 
binding to p67 activates the complex (32). 
Accordingly, we hypothesized that AMPylation 
may inhibit superoxide generation by this 
complex, either by disrupting the interaction 
between p67 and Rac1 or by compromising the 
actin cytoskeleton. To test this we utilized the 
COSphox cell line, which is stably transfected 
with all required components of the NOX2 
system mentioned above (33). Superoxide 
generation was monitored by luminescence for 
30 minutes using the Diogenes kit, and this cell 
based assay was validated by ensuring that 
generation of oxygen radicals upon stimulation 
with the NOX2 activator PMA could be 
inhibited with superoxide dismutase (Fig. 5A).  
COSphox cells were infected with V. 
parahaemolyticus strains for 2 hours, collected, 
and stimulated with PMA for 5 minutes before 
measurement. We found that cells infected with 
CAB5 reduced superoxide generation to levels 
similar to cells that were uninfected and 
uninduced (Fig. 5B). By contrast, cells infected 
with CAB5∆vopS strain generated robust 
superoxide signal upon PMA stimulation. 
Similary, infection with CAB5∆vops/pVopS-
H348A strain containing a plasmid encoding the 
catalytically inactive VopS mutant H348A did 
not inhibit superoxide generation, while 
CAB5∆vopS/pVopS strain reduced superoxide 
generation to levels similar to cells that were 
unstimulated (Fig. 5B). These results indicate 
that targeting of Rho GTPases by pathogens may 
allow them to avoid killing by lymphocytes. 
Interestingly, AMPylation of Rac1 did not 
appear to significantly reduce binding to the 
NOX2 subunit p67 in a GST pulldown assay, in 
contrast to PAK (Fig. 5C, Fig. 2B). This may 
indicate that the inability of these cells to 
generate oxygen radicals may be due other 
molecules involved in the ROS signaling 
pathway. 
Switch-1 AMPylation blocks novel Rac 
interactions-While the above findings support 
the notion that AMPylation of Rho GTPases 
perturb cell signaling beyond a simple loss of 
actin cytoskeleton control, we further 
hypothesized that there may be additional 
unknown roles of Rho GTPases that might be 
disrupted by switch-1 modification. To screen 
for potentially novel interactions, we utilized a 
Nucleic Acid Programmable Protein Array 
(NAPPA) system to probe for Rac1 interacting 
proteins. NAPPA arrays are a robust and rapid 
method of producing thousands of proteins in 
situ for use in personalized diagnostic, post-
translational modification or protein interaction 
screens, among other functions (23,34). 
Compared to protein microarrays fabricated with 
purified proteins, NAPPA instead prints plasmid 
cDNA that can be transcribed and translated 
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using a mammalian cell-free expression system 
on an amino group coated slide. The tagged full-
length proteins expressed are then captured & 
displayed in situ by an anti-tag antibody that was 
printed together with the plasmid DNA (Fig. 
6A). NAPPA has become a rapid method of 
producing thousands of proteins for use in the 
discovery of diseases related antibody 
biomarkers and the identification of novel 
protein-protein interactions (24,35,36).  
To probe for novel Rac1 interactions, 
we expressed a Halo-Rac1 fusion using a human 
cell-free expression system. Lysates containing 
GTP-loaded Halo-Rac1 or Halo alone were 
incubated overnight with NAPPA slides 
presenting more than 10,000 unique proteins, 
followed by washing and labeling with Halo-
ligand fused to alexa660 (Fig. 6A,B). As 
expected, known interactors such as PAK6, 
cIAP1/BIRC2 and XIAP/BIRC4 gave positive 
signals (Fig. 6C). Additionally, a few potentially 
novel interactors were observed, including 
another Rho GTPase, RhoB and the complement 
subunit C1qA (Fig. 5c). C1qA is the first 
component of the serum complement system, a 
secreted ligand binding factor that bridges the 
innate and adaptive immune systems (37).  
We sought to test if AMPylation of the 
switch-1 loop might disrupt any of these novel 
interactions and used a wNAPPA assay to test 
for disrupted interactions as in Fig. 3b. 
Interestingly, the novel interactors RhoA and 
C1qA were able to bind Rac1 in the absence but 
not the presence of VopS (Fig. 7A). This 
observation was further confirmed in an 
immunoprecipitation experiment in which 
recombinantly AMPylated Rac1 was unable to 
bind either GST fused RhoA or C1qA (Fig. 7B). 
These results support the conjecture that Rac1 
mediates additional unknown function(s) in 
innate immunity by binding to C1qA and Rho 
proteins and these interactions are inhibited by 
modification of the switch-1 loop on Rho 
GTPases.  
 
Discussion 
Bacterial pathogens and their multicellular hosts 
are involved in a molecular arms race that has 
stretched through the millennia. Host strategies 
to recognize and clear infections have appeared 
in many evolutionary conserved systems, 
including PRRs, adaptive immunity, and 
inflammatory responses. Pathogens are forced to 
evolve counterstrategies that can weaken or 
thwart these host responses, and they have found 
many critical nodes in signaling pathways to 
subvert for their own survival (26).   
One of these nodes is the Rho family of 
GTPases. While the susceptibility of Rho 
GTPases in relation to their control of the actin 
cytoskeletal has been well documented, it is 
possible that the other functions of these proteins 
in host defense have been overlooked (Fig. 8). 
Here, we sought to explore other potential 
effects of Rho GTPase targeting by a bacterial 
pathogen. Our findings suggest that targeting the 
Rho GTPases may provide some of the same 
NFκB and MAPK inhibition advantages as 
effectors that target the pathways directly (Fig. 
1, 2).  
We found that AMPylation by VopS 
inhibits activation of the NFκB pathway, 
measured by the phosphorylation state of the 
NFκB inhibitor IκBα and the nuclear 
translocation of p65. Activation of the MAP 
kinase JNK was also inhibited, but no change 
was observed in p38 phosphorylation. Loss of 
NFκB and JNK activation by VopS may be 
explained by the previous observation that 
AMPylation of Rho GTPases inhibits interaction 
with PAK (Fig. 3C, (1)), which along with 
Rhotekin is known to signal through these 
pathways (27) However, the crosstalk in these 
immune sensing pathways is complex and not 
completely understood. For example, Rac1 is 
known to be involved in pathogen sensing by 
NOD1, and is also a substrate of the NFκB 
mediator cIAP1. It is possible that AMPylation 
of Rho GTPases inhibits these pathways at 
multiple levels.  
Other factors in the NFκB pathway that 
may be inhibited during V. parahaemolyticus 
infection are the IAP proteins. Ubiquitination by 
IAP proteins is known to be an important for 
NFκB activation, and Rac1 is a known substrate 
of these proteins (17). Cellular Rac and RhoA 
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levels were observed to decrease during late 
stages of V. parahaemolyticus infection with a 
strain lacking VopS, however, the presence of 
VopS appeared to inhibit their degradation. In 
agreement, recombinant Rac1 AMPylated with 
VopS was unable to bind to this E3 ligase, 
which could explain the persistence of Rac1 
levels in the presence of VopS (Fig. 4). 
However, the importance of Rho GTPase 
ubiquitination by IAP proteins for NFκB 
activation has not been determined. The 
combination of NFκB inhibition and loss of IAP 
binding as a result of Rho GTPase AMPylation 
observed in this work indicates that IAP 
ubiquitination of Rho GTPases could be 
important for immune signaling and merits 
further study. Interestingly, the region of Rho 
GTPases involved in binding IAP proteins is not 
known, but these results suggest that the switch-
1 loop plays some role in the interaction, or 
AMPylation causes a conformational change 
that does not allow binding of the E3 ligases. 
Perhaps the most direct and obviously 
beneficial effect of AMPylation by VopS is the 
inability of the phagocytic NADPH oxidase to 
be activated (Fig. 5). This complex is essential 
for fighting bacterial pathogens, as patients 
deficient in any of the complex subunits suffer 
from chronic granulomatous disease with 
recurrent and often deadly infections (38). 
Disabling this host weaponry by targeting the 
Rac GTPases offers bacteria a distinct survival 
advantage. As other bacterial effectors modify 
the switch-1 region of RhoGTPase, this may be 
an overlooked common mechanism used to 
disrupt the host cell activation of ROS. 
Our NAPPA interaction screen has also 
revealed another potential role of Rac1 in innate 
immunity, which is the binding of C1qA (Fig. 
6). As part of the large, secreted complement 
complex, C1qA makes little sense as a signaling 
partner of Rac1, but recent research has revealed 
that C1qA also plays a key cytosolic role in 
innate immunity. C1qA was shown to enhance 
the retinoic acid-inducible gene-I-like receptor 
(RLR) pathway through the binding of several 
cytosolic factors, leading to reduced viral 
replication (39). However, little else is known 
about the cytosolic role of C1qA, particularly in 
regards to bacterial infection. It is possible that 
binding to Rac1 is important for an undiscovered 
function of C1qA in the innate immune system. 
Considering that at least two PRRs for altered 
Rho GTPases exist in the cell, it is possible that 
binding of C1qA to Rac1 is important for one of 
these processes. We observed that AMPylation 
disrupts this interaction, which may serve to 
inhibit or promote the activation of downstream 
signaling (Fig. 7). Dimerization of Rho GTPase 
proteins have been previously observed, but the 
full implication of these and potential Rac1 and 
Rho heterodimers identified in this screen are 
not fully understood. This NAPPA interaction 
system can also be used in the future to screen 
for Rac1 and other Rho GTPase interactions 
against a larger pool of proteins to identify novel 
binding partners and possible activities. 
The sum of the findings presented here 
indicates that the targeting of Rho family 
GTPases provides complex and multifaceted 
advantages for microbial pathogens, highlighting 
the status of Rho GTPases as an “Achilles’ 
Heel” in host immunity (Fig. 8). At least five 
different signaling functions mediated by Rho 
GTPases are sabotaged: collapse of the actin 
cytoskeleton, inactivation of NFκB and JNK 
pathways, lack of degradation of Rho GTPases, 
and lack of superoxides produced by the NOX2 
complex. The critical nature of this modification 
is further supported by recent findings that 
cytosolic PRRs are dedicated to sensing both 
deactivated and over-activated versions of Rho 
GTPases (5,6). As other bacteria use virulence 
factors to inactivate Rho GTPases by modifying 
the switch-1 loop with a variety of post-
translational modifications, the conserved 
mechanisms disrupted by VopS will likely be 
applicable for many other bacterial infection 
models.  
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Figure 1. VopS inhibits activation of NFkB and JNK signaling Phosphorylation and degradation of 
IκBα and JNK phosphorylation is blocked by VopS. HEK293T cells were infected at MOI=10 for the 
indicated times and cells were lysed and immunoblotted for phosphorylation and total protein levels. A 
representative experiment from three trials is presented. IB=immunoblot.  
Figure 2. Nuclear translocation of p65 is inhibited by VopS. A. HEK293T cells were infected for 120 
minutes with indicated strains at MOI=10 prior to fixation, permeabilization and immunofluorescence 
with p65 antibody (Santa Cruz). Mean percentages of cells that have nuclear P65 are indicated with SD (3 
experiments). DNA was visualized with Hoechst stain. Scale bar= 20 µm. B. The percentages of cells that 
have nuclear P65 are indicated. Cell counts are between 75-150 cells from multiple fields for each 
condition and experiment, in three separate experiments. Each data point represents one experiment. 
Asterisk represents P value < 0.01. 
Figure 3. Purification of AMPylated and unmodified His-Rac1 V12. A. Purification of AMPylated 
Rac1. His-Rac1 V12 proteins were expressed in Rosetta E. coli cells with empty vector (His-Rac1 V12) 
or GST-VopS (His-Rac1AMP V12), captured on Nickel affinity resin (Pierce), and applied to a Superdex 
75 column. Rac1 containing fractions were pooled, and purity of final product is shown. B.  Rac1 is 
completely AMPylated. His-Rac1AMP V12 is richly AMPylated as seen with T-AMPylation antibody. A 
secondary VopS AMPylation assay with 32P-α-ATP of the proteins shows that His-Rac1AMP V12 cannot 
be AMPylated further, indicating >95% AMPylation from coexpression. C. AMPylated Rac1 does not 
bind PAK3. 10 ug His-Rac1 V12 proteins were incubated with glutathione beads loaded with GST-PAK3 
Rho binding domain for 2 hours at 4C. Beads were washed and co-eluting Rac1 proteins were observed 
by immunoblot with His antibody. His-Rac1 V12 but not His-Rac1AMP V12 bound PAK3 efficiently. 
PD=pulldown, IB=immunoblot  
Figure 4. AMPylation blocks Rac1 binding to IAP proteins and inhibits Rac1 degradation. A. 
AMPylation inhibits Rac1 binding to IAP proteins. IAP proteins expressed in human cell free lysates 
were incubated with recombinantly purified His-Rac1-V12 or His-Rac1AMP-V12 (see Supplemental Fig. 
1). IAP proteins were then immunoprecipitated with  GST antibody and immunoblotted for interacting 
Rac1 protein with His antibody. B. UnAMPylated but not AMPylated CDC42, RhoA and Rac1 are 
binding partners of IAPs. IAP-GST proteins presented in wNAPPA format were incubated with Halo-
Rac1, CDC42 or RhoA with and without the presence of 5ug of VopS. Binding was measured by 
fluorescein signal after incubation with fluorescein-conjugated Halo ligand. All GTPases were able bind 
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cIAP, but addition of VopS abrogated binding. C. VopS inhibits degradation of Rac1 and RhoA during 
infection. HEK293T cells were infected with indicated strains at MOI of 10 for the indicated times and 
cells were lysed and immunoblotted. Rac and RhoA protein levels were considerably higher at late time 
points in infection in the presence of VopS. IP=immunoprecipitation, IB=immunoblot. Arrowhead 
represents His-Rac1 proteins. Asterisk=non-specific band. 
Figure 5. Superoxide generation by the NOX2 complex is inhibited by VopS during infection. A. 
ROS assay validation. COSphox cells stably transfected with gp91, p22, p47 and p67 were stimulated in 
triplicate by the addition of 2 µM PMA (blue). Cells were collected, induced with PMA for 5 minutes in 
96 well plates, and production of superoxide was measured over 30 minutes using a plate reader. Addition 
of 50 U of SOD (red) completely inhibited the assay, demonstrating that the chemiluminescence is 
superoxide-dependent. Data points are the mean and error bars are standard deviation. PMA= Phorbol 12-
myristate 13-acetate. SOD= Superoxide Dismutase. B. VopS inhibits ROS produced by NOX2. Prior to 
stimulation with PMA as above, COSphox cells were infected in triplicate with the indicated strains at 
MOI 10 for 2 hours. Complementation with wild type VopS reconstituted the inhibition, but 
complementation with catalytically inactive VopS H348A did not. A representative experiment of three 
trials is shown. C. AMPylation does not significantly affect binding of p67 to Rac1. 10 ug His-Rac1 V12 
proteins were incubated with glutathione beads loaded with GST-p67 for 2 hours at 4C. Beads were 
washed and co-eluting Rac1 proteins were observed by immunoblot with His antibody. GST-p67 showed 
only modest reduction in binding His-Rac1AMP-V12 in comparison to His-Rac1-V12. PD=pulldown, 
IB=immunoblot 
Figure 6. NAPPA screen reveals C1qA and as novel Rac1 interacting proteins. A. Schematic of Rac1 
NAPPA 10K screen. Greater than 10,000 cDNA plasmids from the DNASU collection (https://dnasu.org) 
were printed at a density of approximately 2,000 per slide (four slides with C-terminal GST tagged 
proteins and one slide with N-terminal Flag tagged proteins). Expression of printed plasmids was induced 
with human cell free lysates, and the anti-tag antibody that was co-printed with the DNA on NAPPA 
allowed the immobilization of expressed fusion proteins in situ on the array spots. Slides were then 
incubated with Halo alone or Halo-Rac1 fusion protein. After washing, bound Halo-Rac1 was conjugated 
to Fluorescein using Halo ligand and slides were scanned. B. A representative NAPPA slide. Red 
arrowhead=bound Halo-Rac1. C. Rac1 binds multiple proteins in NAPPA screen. Enhanced view of spots 
with bound Halo-Rac1. Arrowheads indicate spot representing labeled prey gene. 
Figure 7. AMPylation inhibits interaction of Rac1 with C1qA and RhoB. A. VopS inhibits binding of 
C1qA and RhoB to Rac1. Indicated prey plasmids were printed in a 96 well ELISA plate coated with anti-
GST antibody prior to cell free expression. Plates were then incubated with Halo-Rac1 with or without 
the addition of 5 ug VopS, washed, and conjugated with Fluorescein-Halo ligand before analysis. 
Addition of VopS inhibited interaction of each of the prey with Halo-Rac1. B. AMPylated Rac1 does not 
bind C1qA or RhoB. C1qA and RhoB proteins expressed in human cell free lysates were incubated with 
recombinantly purified His-Rac1 V12 or His-Rac1AMP V12. GST-fused proteins were then 
immunoprecipitated with GST antibody and immunoblotted for interacting Rac1 protein with His 
antibody. IP=immunoprecipitation, IB=immunoblot 
Figure 8. Rho GTPase AMPylation subverts multiple host signaling processes. Upon translocation 
into the host cell, VopS localizes to the host membrane via its BPD and AMPylates Rho GTPases on their 
switch-1 loop (1). AMPylation inhibits GTPase binding to PAK (2), which compromises cell control of 
the actin cytoskeleton (3). Binding of the E3 ligase to Rac1 is also inhibited, reducing ubiquitin mediated 
degradation (4). Phosphorylation of JNK and IκBα are reduced by VopS (5,6), as is degradation of IκBα 
and nuclear translocation of p65. Production of reactive oxygen species by the Nox2 complex is 
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abrogated, likely promoting bacterial survival from lymphocytes (7). Although the implications of the 
C1qA-Rac1 interaction are unknown, AMPylation blocked this interaction and could inhibit downstream 
signaling (8). 
 
 
 
Table1. Bacterial Strains 
Strains Genotype and Characteristicsa,b,c  Source 
    
Vibrio parahaemolyticus    
 
   
RIMD2210633 Parental clinical isolate of V. parahaemolyticus strains list 
below. KP positive; serotype O3:K6. Not used in this study 
 (40) 
POR3 ∆tdhAS, ∆vcrD2. Allows assessment of T3SS1 activity by 
removing TDH toxins and T3SS2. 
 (41) 
POR3∆vopS ∆tdhAS, ∆vcrD2, ∆vpa1686 (vopS). Allows assessment of 
T3SS1 activity by removing TDH toxins and T3SS2. 
Additional deletion of VopS 
 (1) 
POR3∆vopS/pVopS POR3∆vopS complemented with pLAFR (Tetr) with full 
length VopS and +1kb upstream sequence containing 
endogenous promoter 
 (1) 
CAB5 ∆tdhAS, ∆vtrA, ∆vpa1680 (vopQ), ∆vpa1683 (vopR), 
∆vpa0450. Allows assessment of VopS in isolation by 
removing TDH toxins, T3SS2 and other T3SS1 effectors 
 (7) 
CAB5∆vopS ∆tdhAS, ∆vtrA, ∆vpa1680 (vopQ), ∆vpa1683 (vopR), 
∆vpa1686 (vopS), ∆vpa0450. Strain with deletion of TDH 
toxins and T3SS2, with intact T3SS1 but deletion of all 
characterized T3SS1 effectors incuding VopS 
 (7) 
CAB5∆vopS/pVopS CAB5∆vopS complemented with pBAD33 (Kanr) with full 
length VopS and +1kb upstream sequence containing 
endogenous promoter 
 (7) 
CAB5∆vopS/pVopS H348A CAB5∆vopS complemented with pBAD33 (Kanr) with full 
length VopS H348A (catalytically dead) and +1kb upstream 
sequence containing endogenous promoter 
 This Study 
 
   
Escherichia coli    
 
   
Rosetta/DE3 Allows for high expression of recombinant protein in E. coli Novagen 
a Kanr, kanamycin resistance; Tetr, tetracycline 
resistance 
b TDH, thermostable direct hemolysin 
c T3SS, Type Three Secretion System 
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